JP6910359B2 - Ｎｉｋ阻害剤としての新たな置換されたシアノインドリン誘導体 - Google Patents
Ｎｉｋ阻害剤としての新たな置換されたシアノインドリン誘導体 Download PDFInfo
- Publication number
- JP6910359B2 JP6910359B2 JP2018535876A JP2018535876A JP6910359B2 JP 6910359 B2 JP6910359 B2 JP 6910359B2 JP 2018535876 A JP2018535876 A JP 2018535876A JP 2018535876 A JP2018535876 A JP 2018535876A JP 6910359 B2 JP6910359 B2 JP 6910359B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- het
- substituted
- group
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC1(*)c2cc(-c3nc(C)ncc3*)cc(C#N)c2N(*)C1 Chemical compound CC1(*)c2cc(-c3nc(C)ncc3*)cc(C#N)c2N(*)C1 0.000 description 5
- AVFZOVWCLRSYKC-UHFFFAOYSA-N CN1CCCC1 Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 2
- PAMIQIKDUOTOBW-UHFFFAOYSA-N CN1CCCCC1 Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N CN1CCNCC1 Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
- SJRJJKPEHAURKC-UHFFFAOYSA-N CN1CCOCC1 Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
- RIKMMFOAQPJVMX-UHFFFAOYSA-N Cc1c[nH]nc1 Chemical compound Cc1c[nH]nc1 RIKMMFOAQPJVMX-UHFFFAOYSA-N 0.000 description 2
- XLSZMDLNRCVEIJ-UHFFFAOYSA-N Cc1cnc[nH]1 Chemical compound Cc1cnc[nH]1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 description 2
- LXBGSDVWAMZHDD-UHFFFAOYSA-N Cc1ncc[nH]1 Chemical compound Cc1ncc[nH]1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 2
- MQQWAABQKFXUNL-UHFFFAOYSA-N CC(C)(C)OC(N(CC1(C)CO)c(c(C#N)c2)c1cc2-c1ccnc(Cl)n1)=O Chemical compound CC(C)(C)OC(N(CC1(C)CO)c(c(C#N)c2)c1cc2-c1ccnc(Cl)n1)=O MQQWAABQKFXUNL-UHFFFAOYSA-N 0.000 description 1
- UZOFELREXGAFOI-UHFFFAOYSA-N CC1CCNCC1 Chemical compound CC1CCNCC1 UZOFELREXGAFOI-UHFFFAOYSA-N 0.000 description 1
- OVRKATYHWPCGPZ-UHFFFAOYSA-N CC1CCOCC1 Chemical compound CC1CCOCC1 OVRKATYHWPCGPZ-UHFFFAOYSA-N 0.000 description 1
- UDRSVFVLNKYZKS-AREMUKBSSA-N CCCCc(ccc(C#N)c1)c1Nc1nc(-c2cc(C#N)c3NC[C@](C)(CO)c3c2)ccn1 Chemical compound CCCCc(ccc(C#N)c1)c1Nc1nc(-c2cc(C#N)c3NC[C@](C)(CO)c3c2)ccn1 UDRSVFVLNKYZKS-AREMUKBSSA-N 0.000 description 1
- ULZCOWMSBOJCLT-UHFFFAOYSA-N CN(CC1)CCS1(=O)=O Chemical compound CN(CC1)CCS1(=O)=O ULZCOWMSBOJCLT-UHFFFAOYSA-N 0.000 description 1
- ZKUKXSWKWGHYKJ-UHFFFAOYSA-N CN1CCCCCC1 Chemical compound CN1CCCCCC1 ZKUKXSWKWGHYKJ-UHFFFAOYSA-N 0.000 description 1
- XTGCJRCYGWLUHJ-UHFFFAOYSA-N CN1CCOCCC1 Chemical compound CN1CCOCCC1 XTGCJRCYGWLUHJ-UHFFFAOYSA-N 0.000 description 1
- LEFXMFPHQQMVBG-XMMPIXPASA-N C[C@@]1(CO)c2cc(-c3ccnc(Nc(cc(cc4)Cl)c4OCCOC)n3)cc(C#N)c2NC1 Chemical compound C[C@@]1(CO)c2cc(-c3ccnc(Nc(cc(cc4)Cl)c4OCCOC)n3)cc(C#N)c2NC1 LEFXMFPHQQMVBG-XMMPIXPASA-N 0.000 description 1
- WZVXQMAPQFHWJN-UHFFFAOYSA-N Cc(cc(c(C#N)c1)C#CCN)c1Nc1nc(-c(cc2C=C)cc(C#N)c2NCCCO)ccn1 Chemical compound Cc(cc(c(C#N)c1)C#CCN)c1Nc1nc(-c(cc2C=C)cc(C#N)c2NCCCO)ccn1 WZVXQMAPQFHWJN-UHFFFAOYSA-N 0.000 description 1
- ACANHNHJNYQLAS-UHFFFAOYSA-N Cc1n[nH]c(C2[IH]C2)c1 Chemical compound Cc1n[nH]c(C2[IH]C2)c1 ACANHNHJNYQLAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/535—Organo-phosphoranes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16152416.0 | 2016-01-22 | ||
| EP16152416 | 2016-01-22 | ||
| EP16159651 | 2016-03-10 | ||
| EP16159651.5 | 2016-03-10 | ||
| PCT/EP2017/051150 WO2017125530A1 (en) | 2016-01-22 | 2017-01-20 | New substituted cyanoindoline derivatives as nik inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019504067A JP2019504067A (ja) | 2019-02-14 |
| JP2019504067A5 JP2019504067A5 (https=) | 2020-03-05 |
| JP6910359B2 true JP6910359B2 (ja) | 2021-07-28 |
Family
ID=57868252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018535876A Active JP6910359B2 (ja) | 2016-01-22 | 2017-01-20 | Ｎｉｋ阻害剤としての新たな置換されたシアノインドリン誘導体 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11180487B2 (https=) |
| EP (1) | EP3405196B1 (https=) |
| JP (1) | JP6910359B2 (https=) |
| KR (1) | KR102784966B1 (https=) |
| CN (1) | CN108697710B (https=) |
| AU (1) | AU2017209935B2 (https=) |
| BR (1) | BR112018014675B1 (https=) |
| CA (1) | CA3011880A1 (https=) |
| DK (1) | DK3405196T3 (https=) |
| ES (1) | ES2775449T3 (https=) |
| HR (1) | HRP20200133T1 (https=) |
| HU (1) | HUE047684T2 (https=) |
| IL (1) | IL260500B (https=) |
| LT (1) | LT3405196T (https=) |
| MX (1) | MX2018008974A (https=) |
| PH (1) | PH12018501567A1 (https=) |
| SI (1) | SI3405196T1 (https=) |
| TW (1) | TWI739783B (https=) |
| WO (1) | WO2017125530A1 (https=) |
| ZA (1) | ZA201804688B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2775449T3 (es) | 2016-01-22 | 2020-07-27 | Janssen Pharmaceutica Nv | Nuevos derivados de cianoindolina sustituida como inhibidores de nik |
| EP3405464B1 (en) | 2016-01-22 | 2019-12-04 | Janssen Pharmaceutica NV | New 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors |
| ES2837157T3 (es) | 2016-06-30 | 2021-06-29 | Janssen Pharmaceutica Nv | Derivados de cianoindolina como inhibidores de NIK |
| WO2018002217A1 (en) | 2016-06-30 | 2018-01-04 | Janssen Pharmaceutica Nv | Heteroaromatic derivatives as nik inhibitors |
| JP6740452B2 (ja) * | 2016-07-26 | 2020-08-12 | 深▲セン▼市塔吉瑞生物医▲薬▼有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ，Ｉｎｃ． | プロテインチロシンキナーゼの活性を阻害するためのアミノピリミジン系化合物 |
| KR102704889B1 (ko) * | 2017-09-30 | 2024-09-10 | 하이헤 바이오파마 컴패니 리미티드 | Erk 키나제 억제 활성을 갖는 화합물 및 그의 용도 |
| TW202045008A (zh) | 2019-02-01 | 2020-12-16 | 印度商皮埃企業有限公司 | 4-取代的異噁唑/異噁唑啉(雜)芳基脒化合物、及其製備與用途 |
| US20220177459A1 (en) * | 2019-04-02 | 2022-06-09 | Hinova Pharmaceuticals Inc. | Aromatic amine compound and use thereof in preparation of ar and brd4 dual inhibitors and regulators |
| CN114222737B (zh) | 2019-05-31 | 2024-07-26 | 詹森药业有限公司 | NF-κB诱导激酶的小分子抑制剂 |
| ES2991366T3 (es) | 2020-05-08 | 2024-12-03 | Halia Therapeutics Inc | Inhibidores de NEK7 cinasa |
| US20240285599A1 (en) | 2021-08-23 | 2024-08-29 | Osaka University | Mature-Hepatocyte Transdifferentiation Suppressing Composition |
| US20240158394A1 (en) | 2022-09-14 | 2024-05-16 | Halia Therapeutics, Inc. | Nek7 inhibitors |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001025220A1 (en) | 1999-10-07 | 2001-04-12 | Amgen Inc. | Triazine kinase inhibitors |
| EP1257546A1 (en) | 2000-02-17 | 2002-11-20 | Amgen Inc. | Kinase inhibitors |
| AU2001250783A1 (en) | 2000-02-29 | 2001-09-12 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| EP1373257B9 (en) | 2001-03-29 | 2008-10-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| JP2005500294A (ja) | 2001-06-19 | 2005-01-06 | ブリストル−マイヤーズ スクイブ カンパニー | ホスホジエステラーゼ７に対するピリミジン阻害剤 |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| AU2009263037B2 (en) * | 2008-06-26 | 2011-10-06 | Amgen Inc. | Alkynyl alcohols as kinase inhibitors |
| TWI546290B (zh) | 2008-06-27 | 2016-08-21 | 賽基艾維洛米斯研究股份有限公司 | 雜芳基化合物及其用途 |
| WO2010042337A1 (en) * | 2008-10-07 | 2010-04-15 | Merck Sharp & Dohme Corp. | Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity |
| KR101906146B1 (ko) | 2009-08-17 | 2018-10-10 | 메모리얼 슬로안-케터링 캔서 센터 | 열 충격 단백질 결합 화합물, 조성물, 및 이의 제조 방법 및 사용 방법 |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| BR112013002112B1 (pt) | 2010-07-29 | 2021-04-06 | Rigel Pharmaceuticals, Inc. | Composto, composição farmacêutica, e, uso de um composto, ou de um respectivo sal farmaceuticamente aceitável, ou de uma composição |
| WO2012142329A1 (en) | 2011-04-12 | 2012-10-18 | Myrexis, Inc. | Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors |
| TWI663166B (zh) | 2013-04-24 | 2019-06-21 | 健生藥品公司 | 新化合物 |
| AR093580A1 (es) | 2013-08-30 | 2015-06-10 | Ptc Therapeutics Inc | Inhibidores bmi-1 de pirimidina sustituidos |
| TWI704146B (zh) | 2013-09-26 | 2020-09-11 | 比利時商健生藥品公司 | 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物 |
| TWI627173B (zh) | 2013-09-26 | 2018-06-21 | 比利時商健生藥品公司 | 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物 |
| CN106458990B (zh) | 2014-04-04 | 2019-06-07 | 希洛斯医药品股份有限公司 | 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂 |
| JP2017520526A (ja) | 2014-05-22 | 2017-07-27 | ザ・ユニバーシティ・オブ・シドニー | オメガ−３類似体 |
| WO2016022645A1 (en) | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
| NZ729618A (en) | 2014-09-26 | 2018-07-27 | Gilead Sciences Inc | Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds |
| CN106928216A (zh) | 2015-12-31 | 2017-07-07 | 中国科学院上海药物研究所 | 具有erk激酶抑制活性的化合物、其制备方法和用途 |
| EP3405464B1 (en) | 2016-01-22 | 2019-12-04 | Janssen Pharmaceutica NV | New 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors |
| ES2775449T3 (es) | 2016-01-22 | 2020-07-27 | Janssen Pharmaceutica Nv | Nuevos derivados de cianoindolina sustituida como inhibidores de nik |
| CN109152784B (zh) | 2016-03-16 | 2021-12-28 | 库拉肿瘤学公司 | 经取代的menin-mll抑制剂及使用方法 |
| WO2018002217A1 (en) | 2016-06-30 | 2018-01-04 | Janssen Pharmaceutica Nv | Heteroaromatic derivatives as nik inhibitors |
| ES2837157T3 (es) | 2016-06-30 | 2021-06-29 | Janssen Pharmaceutica Nv | Derivados de cianoindolina como inhibidores de NIK |
-
2017
- 2017-01-20 ES ES17701110T patent/ES2775449T3/es active Active
- 2017-01-20 CN CN201780007786.1A patent/CN108697710B/zh active Active
- 2017-01-20 SI SI201730183T patent/SI3405196T1/sl unknown
- 2017-01-20 BR BR112018014675-7A patent/BR112018014675B1/pt active IP Right Grant
- 2017-01-20 US US16/071,192 patent/US11180487B2/en active Active
- 2017-01-20 HR HRP20200133TT patent/HRP20200133T1/hr unknown
- 2017-01-20 MX MX2018008974A patent/MX2018008974A/es unknown
- 2017-01-20 WO PCT/EP2017/051150 patent/WO2017125530A1/en not_active Ceased
- 2017-01-20 KR KR1020187024257A patent/KR102784966B1/ko active Active
- 2017-01-20 CA CA3011880A patent/CA3011880A1/en active Pending
- 2017-01-20 EP EP17701110.3A patent/EP3405196B1/en active Active
- 2017-01-20 DK DK17701110.3T patent/DK3405196T3/da active
- 2017-01-20 TW TW105143703A patent/TWI739783B/zh not_active IP Right Cessation
- 2017-01-20 HU HUE17701110A patent/HUE047684T2/hu unknown
- 2017-01-20 AU AU2017209935A patent/AU2017209935B2/en active Active
- 2017-01-20 LT LTEP17701110.3T patent/LT3405196T/lt unknown
- 2017-01-20 JP JP2018535876A patent/JP6910359B2/ja active Active
-
2018
- 2018-07-09 IL IL260500A patent/IL260500B/en active IP Right Grant
- 2018-07-13 ZA ZA2018/04688A patent/ZA201804688B/en unknown
- 2018-07-23 PH PH12018501567A patent/PH12018501567A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019504067A (ja) | 2019-02-14 |
| LT3405196T (lt) | 2020-02-25 |
| US20210087182A1 (en) | 2021-03-25 |
| IL260500B (en) | 2021-01-31 |
| WO2017125530A1 (en) | 2017-07-27 |
| KR102784966B1 (ko) | 2025-03-20 |
| HRP20200133T1 (hr) | 2020-05-15 |
| ZA201804688B (en) | 2022-03-30 |
| DK3405196T3 (en) | 2020-03-09 |
| KR20180100441A (ko) | 2018-09-10 |
| EP3405196B1 (en) | 2019-12-04 |
| PH12018501567A1 (en) | 2019-01-28 |
| BR112018014675A2 (pt) | 2018-12-11 |
| CN108697710B (zh) | 2022-02-18 |
| AU2017209935B2 (en) | 2021-04-01 |
| SI3405196T1 (sl) | 2020-03-31 |
| AU2017209935A1 (en) | 2018-08-09 |
| TW201728577A (zh) | 2017-08-16 |
| EP3405196A1 (en) | 2018-11-28 |
| ES2775449T3 (es) | 2020-07-27 |
| HUE047684T2 (hu) | 2020-05-28 |
| BR112018014675B1 (pt) | 2023-12-19 |
| TWI739783B (zh) | 2021-09-21 |
| CA3011880A1 (en) | 2017-07-27 |
| CN108697710A (zh) | 2018-10-23 |
| MX2018008974A (es) | 2018-11-09 |
| US11180487B2 (en) | 2021-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6910359B2 (ja) | Ｎｉｋ阻害剤としての新たな置換されたシアノインドリン誘導体 | |
| JP6936815B2 (ja) | Ｎｉｋ阻害剤としてのヘテロ芳香族誘導体 | |
| JP6916796B2 (ja) | Ｎｉｋ阻害剤としての新たな６員のヘテロ芳香族置換シアノインドリン誘導体 | |
| CA3179692A1 (en) | Fused tricyclic kras inhibitors | |
| CA3157361A1 (en) | Bicyclic heterocycles as fgfr inhibitors | |
| CN107074882B (zh) | 作为nik抑制剂的新的吡唑并嘧啶衍生物 | |
| CN107074881B (zh) | 作为nik抑制剂的新的噻吩并嘧啶衍生物 | |
| JP6936814B2 (ja) | Ｎｉｋ阻害剤としてのシアノインドリン誘導体 | |
| KR20160140739A (ko) | 마크로사이클릭 피리미딘 유도체 | |
| KR102662373B1 (ko) | Nik 억제제로서의 신규 치환 아자인돌린 유도체 | |
| CN121816347A (zh) | 药物化合物 | |
| HK1261385A1 (en) | New substituted cyanoindoline derivatives as nik inhibitors | |
| HK1261385B (en) | New substituted cyanoindoline derivatives as nik inhibitors | |
| EA037358B1 (ru) | Новые замещённые производные цианиндолина в качестве nik-ингибиторов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181003 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200120 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200120 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200210 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20200601 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20200625 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201222 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20201224 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210317 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210622 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210706 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6910359 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |